Medical marijuana refers to cannabis or cannabis-derived products used under a healthcare provider’s guidance to treat symptoms of specific medical conditions. The cannabis plant contains over a hundred active compounds called cannabinoids, but the two that matter most for medicine are THC (the one that gets you high) and CBD (which does not). These compounds interact with a signaling network your body already has, and that interaction is what gives medical cannabis its therapeutic effects and its risks. The story is more nuanced than either its advocates or its critics tend to let on, with strong evidence for some uses and surprisingly thin evidence for others.
How Cannabis Works in the Body
Your body runs its own cannabis-like signaling system called the endocannabinoid system. It uses naturally produced molecules that bind to two types of receptors, CB1 and CB2, found throughout the brain and body. CB1 receptors are concentrated in the central nervous system, while CB2 receptors appear mainly on immune cells. This system helps regulate pain, mood, appetite, inflammation, and memory, among other things.
THC, the main psychoactive compound in cannabis, works by partially activating both CB1 and CB2 receptors, essentially mimicking the molecules your body already makes but doing so more powerfully and for longer.1PubMed Central. Review of the Endocannabinoid System That CB1 activation is responsible for the euphoria, altered perception, pain relief, and appetite stimulation that cannabis is known for. CBD, by contrast, does not bind to those receptors the same way. It actually appears to work partly as an antagonist at CB1 and CB2 receptors, which may explain why it can dampen some of THC’s effects and why it does not produce a high.2PubMed Central. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin Despite sharing a chemical parent, THC and CBD differ dramatically in how they affect brain function.3PubMed Central. THC and CBD: Similarities and differences between siblings
The Entourage Effect
Cannabis contains more than just THC and CBD. It also produces terpenes, the aromatic compounds responsible for the plant’s distinctive smell, along with dozens of minor cannabinoids. The “entourage effect” is the idea that these compounds work better together than any single one does alone.4PubMed Central. The “Entourage Effect”: Terpenes Coupled with Cannabinoids for the Treatment of Mood Disorders and Anxiety Disorders Lab research has found that certain terpenes do appear to boost THC’s activation of the CB1 receptor beyond what you would expect from simply adding the effects together, suggesting genuine synergy rather than just an additive boost.5PubMed. Selected cannabis terpenes synergize with THC to produce increased CB1 receptor activation
That said, the clinical significance of the entourage effect is far from settled. While the concept is popular in patient communities and dispensary marketing, a comprehensive review concluded that the potential for terpenes to meaningfully enhance cannabinoid therapy in humans remains unproven and needs proper clinical trials to confirm.6PubMed Central. The Entourage Effect in Cannabis Medicinal Products: A Comprehensive Review The gap between promising lab findings and proven clinical benefit is one of the recurring themes in cannabis medicine.
What Conditions Does Medical Marijuana Treat?
The strength of evidence varies enormously depending on the condition. A handful of uses have solid clinical trial support, while many others rest on preliminary research, observational data, or patient self-reports.
Chronic Neuropathic Pain
Pain is the single most common reason people seek medical cannabis, and neuropathic pain specifically (nerve damage from conditions like diabetes, spinal cord injury, or HIV) has the strongest evidence base. A Cochrane review of cannabis-based medicines for chronic neuropathic pain found that roughly 39% of patients achieved at least a 30% reduction in pain, compared to about 33% on placebo.7PubMed Central. Cannabis‐based medicines for chronic neuropathic pain in adults That is a modest advantage, but for people who have failed other treatments, even modest improvements matter. A separate meta-analysis found statistically significant pain reductions for both THC-only and THC/CBD combination products compared to placebo on a standard pain scale.8PubMed Central. Efficacy of cannabis-based medications compared to placebo for the treatment of chronic neuropathic pain: a systematic review with meta-analysis
One interesting finding from a trial of vaporized cannabis was that low doses were just as effective as medium doses for neuropathic pain, with a number-needed-to-treat comparable to traditional neuropathic pain drugs.9PubMed Central. Low-dose vaporized cannabis significantly improves neuropathic pain This matters practically: lower doses mean fewer side effects, and it suggests that patients do not necessarily need to get particularly high to get pain relief.
Epilepsy
CBD-based treatment for epilepsy is the area where cannabis medicine has its strongest regulatory endorsement. The FDA approved a purified CBD product (Epidiolex) in 2018 for patients two years and older with Dravet syndrome or Lennox-Gastaut syndrome, two severe forms of childhood epilepsy that resist conventional medications.10PubMed Central. Emerging Use of Epidiolex (Cannabidiol) in Epilepsy In double-blind trials, CBD reduced seizure frequency meaningfully: one study in children with Dravet syndrome showed about a 23% reduction in seizures, while studies of Lennox-Gastaut syndrome patients reported reductions in drop seizures of around 42–44%.11PubMed Central. Medical cannabis for severe treatment resistant epilepsy in children: a case-series of 10 patients These numbers are not miraculous cures, but for children experiencing dozens or hundreds of seizures per month despite multiple other medications, they represent a real clinical advance.
Multiple Sclerosis Symptoms
Nabiximols, a mouth spray containing both THC and CBD, has been shown to improve spasticity and pain in people with multiple sclerosis. A review of the evidence found that both the spray and oral cannabinoids were effective for MS-related pain and muscle stiffness, though results for other MS symptoms like bladder dysfunction were less consistent.12PubMed Central. The Efficacy of Cannabis on Multiple Sclerosis-Related Symptoms Nabiximols is approved in several countries outside the United States for this use.
Chemotherapy-Induced Nausea and Appetite Loss
This is one of the oldest medical uses of cannabis, and there is conclusive evidence that oral cannabinoids are effective for chemotherapy-induced nausea and vomiting.13PubMed Central. Opportunities for cannabis in supportive care in cancer Synthetic THC (dronabinol) has been FDA-approved for this purpose since the 1980s. THC is also known to boost appetite, which matters for cancer patients dealing with wasting. However, a systematic review of cannabis products in palliative care found that the overall evidence for cancer-related pain and gastrointestinal symptoms was still limited, with mixed results for insomnia and mood disorders in palliative settings.14PubMed Central. Review of the Use of Medicinal Cannabis Products in Palliative Care
PTSD
Many patients with post-traumatic stress disorder report that cannabis helps with sleep disturbances, anxiety, and intrusive memories. An analysis of patients from the UK Medical Cannabis Registry found significant improvements in PTSD symptoms, sleep, and anxiety across follow-up periods.15PubMed. Assessment of clinical outcomes in patients with post-traumatic stress disorder: analysis from the UK Medical Cannabis Registry There is growing neurobiological evidence and animal research suggesting plausible mechanisms for why cannabinoids might help with PTSD, but the clinical literature also reveals a troubling correlation between PTSD and problematic cannabis use, making it hard to disentangle genuine treatment effects from self-medication patterns.16PubMed Central. The Use of Medicinal Marijuana for Posttraumatic Stress Disorder: A Review of the Current Literature
How Medical Cannabis Is Taken
Route of administration matters more than most patients realize, because it changes how quickly the drug works, how long it lasts, and how much actually reaches the bloodstream. When cannabis is inhaled (whether smoked or vaporized), THC enters the blood through the lungs and reaches peak levels within about 6 to 10 minutes. Bioavailability through inhalation ranges from roughly 10% to 35%. When swallowed as an edible, oil, or capsule, THC must pass through the digestive system and liver first. This slows the onset to 30 minutes to two hours and drops bioavailability to just 4–12%.17PubMed Central. Mechanisms of Action and Pharmacokinetics of Cannabis
This pharmacokinetic difference creates a practical trap for new users. Because edibles take so long to kick in, people sometimes eat more thinking the first dose did not work, and then find themselves overwhelmed an hour later when everything hits at once. Inhalation gives faster feedback, making it easier to control dosing, but carries its own respiratory downsides discussed below. Sublingual sprays and tinctures (held under the tongue) offer a middle ground with somewhat faster absorption than edibles.
Risks and Side Effects
The risks of medical cannabis are real and underappreciated in some patient communities, partly because the “natural” framing leads people to assume it is inherently gentle. The side-effect profile depends heavily on the product, the dose, the route, and the person.
Dependence and Cannabis Use Disorder
One of the more sobering findings in recent research is that cannabis use disorder (CUD) is not rare among medical users. A systematic review and meta-analysis found that about 25% of people using medicinal cannabis met diagnostic criteria for CUD.18PubMed. The prevalence of cannabis use disorders in people who use medicinal cannabis: A systematic review and meta-analysis That is a strikingly high rate, though it should be read carefully: the criteria for CUD include things like tolerance (needing more to get the same effect) and using more than intended, which can overlap with legitimate medical dose adjustments. Still, people with chronic pain and those with pre-existing mental health conditions had elevated risk.
Mental Health Risks
Regular use of high-THC products by adolescents and young adults is associated with a roughly two-fold to eleven-fold increased risk of psychosis, higher odds of developing CUD, and self-harm in people with mood disorders.19JAMA Internal Medicine. Cannabis and Mental Health: A Review Longitudinal studies have consistently shown that regular cannabis use predicts an increased risk of schizophrenia and psychotic symptoms, even after controlling for other factors like other drug use and pre-existing personal characteristics.20PubMed Central. Cannabis use and the risk of developing a psychotic disorder The risk is highest for young people and heavy users, and it likely interacts with genetic vulnerability, but dismissing it as irrelevant to medical users would be a mistake, especially for younger patients.
Respiratory and Cardiovascular Effects
Smoking cannabis produces many of the same respiratory irritants as tobacco smoke. Chronic cannabis smoking has been linked to cough, excess mucus production, and wheezing that resembles chronic bronchitis. These symptoms tend to clear up when someone stops smoking, suggesting the damage is inflammatory rather than structural, and unlike tobacco, cannabis smoking does not consistently cause emphysema.21PubMed Central. Cannabis use and its impact on respiratory physiology and lung cancer risk: Mechanistic and epidemiological insights A systematic review of administration routes found that smoking was the route most associated with respiratory problems (bronchitis, shortness of breath) and cardiovascular effects including rapid heartbeat and, in rarer cases, irregular heart rhythms. Edibles carried minimal respiratory risk, though a fast heartbeat was reported across all routes.22PubMed. Cardiovascular and Respiratory Effects of Cannabis Use by Route of Administration: A Systematic Review The American Heart Association has flagged cardiovascular concerns as an area warranting caution, particularly for people with existing heart conditions.23PubMed. Medical Marijuana, Recreational Cannabis, and Cardiovascular Health: A Scientific Statement From the American Heart Association
Driving Impairment
Cannabis impairs driving, full stop. A randomized clinical trial found that THC significantly impaired driving performance at 30 minutes and 90 minutes after use, with the effect fading by about four and a half hours.24JAMA Psychiatry. Driving Performance and Cannabis Users’ Perception of Safety: A Randomized Clinical Trial Acute cannabis intoxication slows reaction time and impairs executive function, which are exactly the skills that matter when you need to stop at a red light or react to something unexpected on the road.25PubMed Central. Cannabis Effects on Driving Performance: Clinical Considerations Unlike alcohol, there is no widely agreed-upon blood-level threshold for cannabis impairment, which creates challenges for both patients and law enforcement.
Cannabinoid Hyperemesis Syndrome
One of the more paradoxical risks is cannabinoid hyperemesis syndrome (CHS), a condition where a substance known for treating nausea causes severe, uncontrollable vomiting in some heavy, long-term users. Cannabis has a biphasic effect on the gut: at low doses it reduces nausea, but at higher doses and with chronic use it can become pro-emetic.26PubMed Central. Cannabis hyperemesis syndrome: an update on the pathophysiology and management CHS episodes feature cyclic nausea and vomiting, abdominal pain, and a distinctive compulsion to take hot showers (which temporarily relieves symptoms in most patients). Standard anti-nausea medications often fail, and the only reliable long-term treatment is stopping cannabis entirely.27PubMed Central. Cannabinoid Hyperemesis Syndrome: Diagnosis, Pathophysiology, and Treatment-a Systematic Review CHS is likely underdiagnosed because many patients and even some clinicians do not connect cannabis with vomiting.
Drug Interactions
Both THC and CBD can interfere with the liver enzymes your body uses to process other medications. CBD in particular is a potent inhibitor of several of these enzymes. The most clinically relevant interaction involves the enzyme CYP2C9, which is inhibited by nearly all major cannabinoids at concentrations that could occur in patients. This matters because CYP2C9 processes several common drugs including the blood thinner warfarin and certain anti-seizure medications.28PubMed. Cannabinoid Interactions with Cytochrome P450 Drug Metabolism: a Full-Spectrum Characterization If you are taking medications with a narrow safety margin, adding cannabis products without medical supervision can push blood levels of those drugs into dangerous territory. Anyone on prescription medications should discuss cannabis use with their doctor or pharmacist.
The Legal Landscape
In the United States, cannabis occupies an unusual legal gray zone. Under federal law, it remains a Schedule I controlled substance, defined as having no accepted medical use and a high potential for abuse.29Mayo Clinic Proceedings. Medical Cannabis State and Federal Regulations: Implications for United States Health Care Entities Meanwhile, a majority of states have passed their own laws permitting medical cannabis in some form. These state laws vary enormously in what conditions qualify, how products are regulated, and what forms of cannabis are allowed. Hemp-derived products (containing less than 0.3% THC) were removed from the federal Schedule I list by the 2018 Farm Bill, which is why CBD products are sold widely in stores, though the regulatory framework around them remains murky.30PubMed. Legal and Regulatory Aspects of Medical Cannabis in the United States
This federal-state conflict creates real practical headaches. Doctors cannot technically “prescribe” cannabis the way they prescribe other medications; instead, in states with medical programs, they write a “recommendation” or “certification.” Patients who move between states may find their qualifying condition is covered in one state but not another. And healthcare institutions that receive federal funding walk a legal tightrope. The inconsistency has contributed to widespread uncertainty among both providers and patients about what is actually legal and how to navigate the system.
Internationally, the picture varies just as much. The United Kingdom permits cannabis-based medicines through a framework established in 2018, though access in practice has been limited. The European Union leaves regulation largely to individual member states, creating a patchwork across the continent. Countries like Canada and Uruguay have gone further with full legalization.
Product Quality and Contamination
Because medical cannabis sits outside the normal pharmaceutical pipeline in most places, product quality is inconsistent. Unlike a drug that went through FDA approval, a cannabis product from a dispensary may not have been tested to pharmaceutical standards. There is a widely acknowledged need for standardized regulations to ensure product quality and safety across the industry.31PubMed Central. A Clinical Framework for Evaluating Cannabis Product Quality and Safety
Common contaminants in cannabis include microbes (bacteria and fungi), heavy metals, and pesticide residues. The direct human health effects of these contaminants are not well quantified, but they carry risks including infection (particularly for immunocompromised patients), potential carcinogenicity from certain pesticides, and reproductive harm from heavy metals.32PubMed Central. Cannabis contaminants: sources, distribution, human toxicity and pharmacologic effects Some states require third-party lab testing for potency and contaminants, but the rigor and enforcement of those standards vary. Patients should look for products that come with certificates of analysis from independent labs, and immunocompromised individuals need to be particularly cautious about microbial contamination.
Older Adults and Medical Cannabis
Older adults are one of the fastest-growing demographics of medical cannabis users, typically seeking relief from chronic pain, insomnia, or the symptoms of neurodegenerative conditions. An observational study of elderly medical cannabis patients found the treatment was generally safe and effective, and that cannabis use was associated with decreased use of other prescription medications, including opioids.33PubMed. Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly That last point is often cited as a potential benefit in the context of the opioid crisis.
However, the evidence base has a blind spot here. Almost all of the controlled cannabis trials that exist enrolled participants under age 60, meaning the dosing information and risk profiles were not established in older bodies.34PubMed. Medical Cannabis for Older Patients Older adults are more vulnerable to cannabis-related dizziness and instability, which raises fall risk. They are also more likely to be on multiple medications, making the drug-interaction issue described earlier more relevant. Cognitive effects, even subtle ones, are a concern in a population already at elevated risk for dementia. A review of recent research concluded that while medical cannabis appears generally well tolerated in older adults, neurocognitive consequences and cardiovascular risks have been reported, and the findings so far are inconsistent enough that caution is warranted.35PubMed Central. Medical Cannabis Use and Its Impact on Health Among Older Adults: Recent Research Findings and Future Directions Starting low and going slow is the practical mantra for this group.
Palliative Care and End-of-Life Use
In palliative settings, where the goal shifts from curing disease to managing symptoms and preserving quality of life, cannabis-based products have been explored for pain, nausea, appetite loss, sleep, and agitation. A meta-analysis looking across palliative populations found positive treatment effects for some cannabis products on pain, nausea and vomiting, appetite, sleep, and fatigue in cancer patients, as well as on appetite and agitation in patients with dementia.36Journal of Pain and Symptom Management. Medicinal Cannabis in Palliative Care: A Systematic Review and Meta-Analysis The appeal of cannabis in this context is partly about the range of symptoms it may address simultaneously, potentially allowing patients to reduce their overall medication burden.
Clinicians in palliative care tend to view cannabis as one tool in a larger toolbox, not a replacement for established treatments. For patients who are already on high doses of opioids for pain and anti-emetics for nausea, cannabis may offer additional relief or allow dose reductions in those other drugs. But the evidence here remains limited, and much of it comes from observational studies rather than controlled trials. Patients in palliative care are, by definition, among the most medically complex, and the drug-interaction considerations for someone on a dozen medications are real and individualized.